Literature DB >> 23618860

Differential regulation of cyclin-dependent kinase inhibitors in neuroblastoma cells.

Lan Qiao1, Pritha Paul, Sora Lee, Jingbo Qiao, Yongsheng Wang, Dai H Chung.   

Abstract

Gastrin-releasing peptide (GRP) and its receptor (GRP-R) are highly expressed in undifferentiated neuroblastoma, and they play critical roles in oncogenesis. We previously reported that GRP activates the PI3K/AKT signaling pathway to promote DNA synthesis and cell cycle progression in neuroblastoma cells. Conversely, GRP-R silencing induces cell cycle arrest. Here, we speculated that GRP/GRP-R signaling induces neuroblastoma cell proliferation via regulation of cyclin-dependent kinase (CDK) inhibitors. Surprisingly, we found that GRP/GRP-R differentially induced expressions of p21 and p27. Silencing GRP/GRP-R decreased p21, but it increased p27 expressions in neuroblastoma cells. Furthermore, we found that the intracellular localization of p21 and p27 in the nuclear and cytoplasmic compartments, respectively. In addition, we found that GRP/GRP-R silencing increased the expression and accumulation of PTEN in the cytoplasm of neuroblastoma cells where it co-localized with p27, thus suggesting that p27 promotes the function of PTEN as a tumor suppressor by stabilizing PTEN in the cytoplasm. GRP/GRP-R regulation of CDK inhibitors and tumor suppressor PTEN may be critical for tumoriogenesis of neuroblastoma.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23618860      PMCID: PMC3754446          DOI: 10.1016/j.bbrc.2013.04.023

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

1.  Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas.

Authors:  Pritha Paul; Lauren A Gillory; JungHee Kang; Jingbo Qiao; Dai H Chung
Journal:  Surgery       Date:  2010-10-29       Impact factor: 3.982

Review 2.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

3.  Phosphatidylinositol 3-kinase regulation of gastrin-releasing peptide-induced cell cycle progression in neuroblastoma cells.

Authors:  Titilope A Ishola; JungHee Kang; Jingbo Qiao; B Mark Evers; Dai H Chung
Journal:  Biochim Biophys Acta       Date:  2007-02-20

Review 4.  p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Authors:  Seth A Wander; Dekuang Zhao; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2010-10-21       Impact factor: 12.531

Review 5.  The function of p27 KIP1 during tumor development.

Authors:  Jinhwa Lee; Sung Soo Kim
Journal:  Exp Mol Med       Date:  2009-11-30       Impact factor: 8.718

Review 6.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 7.  The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.

Authors:  Isabel M Chu; Ludger Hengst; Joyce M Slingerland
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

Review 8.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

9.  Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma.

Authors:  Jingbo Qiao; Junghee Kang; Titilope A Ishola; Piotr G Rychahou; B Mark Evers; Dai H Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

10.  Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM.

Authors:  Laura Fontana; Micol E Fiori; Sonia Albini; Loredana Cifaldi; Serena Giovinazzi; Matteo Forloni; Renata Boldrini; Alberto Donfrancesco; Valentina Federici; Patrizio Giacomini; Cesare Peschle; Doriana Fruci
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

View more
  4 in total

1.  Action of HMGB1 on miR-221/222 cluster in neuroblastoma cell lines.

Authors:  Emanuela Mari; Alessandra Zicari; Flavia Fico; Isabella Massimi; Lolli Martina; Stefania Mardente
Journal:  Oncol Lett       Date:  2016-07-18       Impact factor: 2.967

Review 2.  Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.

Authors:  Akari Minami; Atsuko Nakanishi; Yasunori Ogura; Yasuko Kitagishi; Satoru Matsuda
Journal:  Front Oncol       Date:  2014-11-10       Impact factor: 6.244

3.  The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma.

Authors:  Mario Capasso; Lee D McDaniel; Flora Cimmino; Andrea Cirino; Daniela Formicola; Mike R Russell; Pichai Raman; Kristina A Cole; Sharon J Diskin
Journal:  J Cell Mol Med       Date:  2017-06-30       Impact factor: 5.310

Review 4.  Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.